Tiny blood molecules may reveal lung damage in cystic fibrosis

NCT ID NCT02992080

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates whether tiny molecules in the blood, called miRNAs, can act as markers of lung disease in people with cystic fibrosis. Researchers will compare miRNA patterns between cystic fibrosis patients and healthy volunteers, and also between patients with mild versus severe lung disease. The goal is to find a simple blood test that could help monitor lung health without invasive procedures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a simple blood test to monitor lung disease in cystic fibrosis, helping doctors tailor treatments earlier.

What could go wrong

This is an early observational study, not a treatment trial. The identified miRNA patterns may not prove reliable enough for routine use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Montpellier University Hospital

    Montpellier, 34295, France

  • Necker Hospital

    Paris, 75015, France